Cartesian Therapeutics (RNAC) Change in Cash (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Change in Cash data on file, last reported at -$6.5 million in Q1 2026.

• On a quarterly basis, Change in Cash rose 79.8% year-over-year to -$6.5 million in Q1 2026; TTM through Mar 2026 was -$61.7 million, a 179.85% decrease from a year earlier, with the FY2025 full-year figure at -$87.4 million, down 164.27% from the prior year.
• Change in Cash for Q1 2026 stood at -$6.5 million, up from -$18.2 million in the prior quarter.
• Over the last five years, Change in Cash for RNAC reached as high as $132.0 million in Q3 2024 and fell as low as -$34.0 million in Q3 2023.
• Historically, Change in Cash has averaged $290588.2 across 5 years, with a median of -$6.6 million in 2024.
• On a YoY basis, Change in Cash climbed as much as 7098.83% in 2022 and fell as far as 989.29% in 2022.
• Year by year, Change in Cash stood at -$6.4 million in 2022, then soared by 57.97% to -$2.7 million in 2023, then plunged by 144.73% to -$6.6 million in 2024, then sank by 176.94% to -$18.2 million in 2025, then jumped by 64.38% to -$6.5 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were -$6.5 million in Q1 2026, -$18.2 million in Q4 2025, and -$16.9 million in Q3 2025.